C
PVLA

Certuity’s Palvella Therapeutics PVLA Stock Holding History

Certuity’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$458K Hold
3,000
– – 0.02% 376
2026
Q1 		$374K Hold
3,000
– – 0.02% 374
2025
Q4 		$314K Buy
+3,000
New +$256K 0.02% 399

Other funds holding PVLA

CAM
Clio Asset Management Charlottesville, Virginia $126M AUM 16.01% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $4.05B AUM 19.01% 1-Year Est. Return
MUAMU
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $215M AUM 47.21% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Certuity's PVLA Position: Q2 2026 in Review

Certuity held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 3,000 shares worth $458K. The position accounts for 0.02% of the portfolio, ranked #376.

Certuity first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 23 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Certuity held 3,000 shares of Palvella Therapeutics worth $458K as of Q2 2026.
  • Certuity left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up 0.02% of Certuity's portfolio in Q2 2026, its #376 holding.
  • Certuity first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 23 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Certuity's 13F filing for Q2 2026, filed 28 Jul 2026.